Kidney cancer is the most common cancer in the world around 63,990 new cases are estimated to be in 2017. Among the primary kidney cancer, renal parenchymal cancer is the most common estimating around 80-90% and it is the most complex to treat. The chances of developing cancer is about 1 in 63 in lifetime, with higher risk in men than women. There is rise in the incidences of renal cell carcinoma in recent decade, due to unhealthy lifestyle such as smoking, obesity and decline in physical activity. Thus, with increase in aged population and growth in incidences of kidney cancer and drugs in pipeline for approval would drive the growth of kidney cancer drug market.
The report titled “Kidney Cancer/Renal Cell Carcinoma Drugs Market - Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the overall kidney cancer drugs market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drug and different geographies. Further cross-sectional presented in terms of drug and constituent region/country level markets is also included in this section.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global kidney cancer drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global kidney cancer/renal cell cancer drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global kidney cancer/renal cell carcinoma drugs market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report.
Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the vascular grafts market. The key players profiled in this report are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., GlaxoSmithKline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.
Renal cell carcinoma is the most common type of cancer observed in developed countries. Surgical treatment do not suffice at times and need other additional treatments. Most promising treatment is target therapies that are commonly used for of kidney cancer. Sutent, Nexavar, Votrient are commonly used drugs for renal cell carcinoma treatment. Sutent occupies the largest share, thus dominating the kidney cancer drugs market. It is most commonly prescribed first line treatment drug for renal cell carcinoma. Votrient is anticipated to be the fast growing market in the forecast period. With patent expiry of branded drugs, entry of generics would affect the kidney cancer drugs market negatively. However, novel drugs in phase 2 and 3 of clinical trials would further propel the growth of kidney cancer drugs market.
In 2021, North America occupies the major share of kidney cancer drugs market followed by Europe. North America and Europe have the highest incidences of kidney cancer and lowest is found in Africa and Asia. It is observed that kidney cancer is more prevalent in developed region around 59%. In U.S. around 65,000 new cases are diagnosed each year and 13,500 deaths occur due to renal cell carcinoma annually. It is the seventh most common cancer in men and the ninth most common in women. Rise in incidences of kidney cancer, well established healthcare infrastructure and favorable reimbursement policies are some of the key reasons for growth of kidney cancer/renal cell carcinoma drugs market in North America. Asia Pacific is the fastest growing kidney cancer/renal cell carcinoma drugs market. Rising geriatric population, improvement in overall healthcare infrastructure, increase in patient awareness availability of generics and improved diagnostic technology are the key reason for the growth of lucrative Asia Pacific market.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Kidney Cancer/Renal Cell Carcinoma (RCC) Drugs market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Type
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
